Trial Profile
Dendritic-cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesothelioma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Autologous dendritic cell vaccine Amphera (Primary) ; Cyclophosphamide
- Indications Malignant-mesothelioma
- Focus Adverse reactions
- 08 Jun 2021 Results of a pooled analysis assessing the long-term survival of the patients treated with dendritic cell in these three phase 1 studies presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 15 Nov 2010 Planned end date changed from 10 Jan 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 15 Nov 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).